1. Scrip
  2. >>Business

Pfizer’s RSV Vaccine Springs Another Surprise, This Time In Maternal Use

Could Seize Share From Sanofi - Analysts

 
• By Andrew McConaghie

Sanofi’s monoclonal antibody is still expected to lead the market in respiratory syncytial virus, but Pfizer may have just overturned expectations about maternal vaccination with its product.

Pregnant woman vaccine
Interim analysis of the Phase IIb study showed 85% efficacy against RSV infection for infants born to vaccinated mothers.

Pfizer Inc has released data from its maternal respiratory syncytial virus (RSV) vaccine candidate which suggest strong efficacy, and could see it take a bigger than expected slice of a soon-to-be multi-billion dollar market.

An abstract from a Phase IIb study being presented at the RSV Vaccines for the World Conference (RSVVW) conference (being held on 10-11 November) marks the first efficacy data from Pfizer’s RSVpreF vaccine, and shows it to reach 85% efficacy

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Scrip